drugset / Trial / NCT06315478

Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians

NCT06315478

Phase 4 Completed 60 enrolled Helwan University
RandomizedSequentialOpen-labelTreatment

Summary

Our study aimed to investigate the efficacy and safety of hybrid regimen as a first line therapy for H. pylori eradication compared to triple and quadruple regimens in attempt to overcome antibiotic resistance

Timeline

Start
2021-02-01
Primary completion
2021-03-16
Completion
2021-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 500 mg
Comparator Clarithromycin Small molecule 500 mg
Comparator Metronidazole Small molecule 500 mg
Comparator Omeprazole Other / unclassified 20 mg Oral